{
    "Trade/Device Name(s)": [
        "Coag-Sense Prothrombin Time (PT) / INR Monitoring System",
        "Coag-Sense Prothrombin Time (PT) / INR Monitoring Device"
    ],
    "Submitter Information": "CoaguSense, Inc.",
    "510(k) Number": "K183255",
    "Predicate Device Reference 510(k) Number(s)": [
        "K050243",
        "K093243"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GJS"
    ],
    "Summary Letter Date": "November 19, 2018",
    "Summary Letter Received Date": "November 21, 2018",
    "Submission Date": "December 20, 2018",
    "Regulation Number(s)": [
        "21 CFR 864.7750"
    ],
    "Regulation Name(s)": [
        "Prothrombin time test"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Prothrombin Time (PT)",
        "International Normalized Ratio (INR)"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Coag-Sense PT/INR Monitoring System"
    ],
    "Method(s)/Technology(ies)": [
        "Micro-mechanical end point detection",
        "Infrared light beam detection",
        "Direct clot formation detection"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Instrument",
        "Test strip",
        "Meter"
    ],
    "Document Summary": "FDA 510(k) summary for Coag-Sense PT/INR Monitoring System for quantitative measurement of prothrombin time and INR in capillary whole blood for anticoagulation therapy monitoring.",
    "Indications for Use Summary": "For professional and self-test use to monitor patients stabilized on warfarin-type anticoagulation therapy by providing quantitative PT and INR results using fresh capillary whole blood; not intended for screening purposes.",
    "fda_folder": "Hematology"
}